Genomic Looks to Diversify Offering - Analyst Blog
January 10 2012 - 10:15AM
Zacks
Over the recent past,
Genomic Health (GHDX), an oncology based biotech
company, has been working on several pipeline programs to reduce
dependence on its flagship product, Oncotype DX breast cancer test.
The company to that end initiated a large validation study of its
prostate cancer test in collaboration with the University of
California, San Francisco.
The study hopes to determine
whether a multi-gene test can help distinguish an aggressive
disease (that will require surgery) from a less aggressive one in
patients with early-stage prostate cancer. Complete results are
expected to be presented in early 2012. A positive outcome could
lead to the launch of the Oncotype DX prostate cancer test in 2013.
This will enable physicians to better assess the risk of a
particular patient, facilitating the selection of the appropriate
treatment option.
Genomic Health is also progressing
with its Next Generation Sequencing (NGS) program with the
initiation of clinical development studies. The studies will
examine both RNA-Seq expression and mutation analysis. This
decision comes on the back of a successful clinical outcomes study
for biomarker discovery using NGS for whole transcriptome profiling
of archival FFPE tumor specimens.
The CEO at Genomic Health, Kim
Popovits will provide a business update today at the JP Morgan
Healthcare Conference. He will highlight the company's achievements
and its priorities for 2012. The company’s recent achievement
includes the successful launch of the Oncotype DX DCIS Score and
MMR colon cancer testing service.
Having established a strong
foothold in the US market, Genomic Health is targeting the
international arena. However, securing reimbursement outside the US
is a major deterrent to expanding the overseas business. The
company expects revenue from the international market to be an
important driver of top-line growth in 2012. We believe favorable
data from the various ongoing studies might help the company in
securing reimbursements.
Besides facing increasing
competition from players such as Myriad Genetics
(MYGN) and Cepheid (CPHD), operating expense is on
an uptrend due to higher investments in international expansion,
pipeline development and product launches.
Genomic Health currently retains a
Zacks #3 Rank (short-term Hold rating). We also maintain our
long-term Neutral recommendation on the stock.
CEPHEID INC (CPHD): Free Stock Analysis Report
GENOMIC HEALTH (GHDX): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From May 2024 to Jun 2024
Cepheid (NASDAQ:CPHD)
Historical Stock Chart
From Jun 2023 to Jun 2024